Watch RGNX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
49
WATCH · insiders 79, shorts 19
Insiders, 90 days
+$949K
net buying · 2 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $590.2MP/E —DIV YIELD —FCF YIELD -42.31%REV TTM $174.5M +12.0%NET INCOME −$196.4MNET CASH —52W 5.65 – 15.98NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $108M | +405.7% | — | $29.3M | $22.7M | — | 0.43 | −$62.2M | $760K | −$63M | Aug 6 |
| Q1 2026 · Mar 31 | $6.4M | −92.8% | — | −$83.4M | −$90.1M | −1580.4% | -1.72 | −$76.2M | $1.2M | −$77.4M | May 14 |
| Q4 2025 · Dec 31derived | $30.3M | +43.0% | — | −$57.6M | −$67.1M | — | -1.30 | −$52.3M | $508K | −$52.8M | Mar 5 |
| Q3 2025 · Sep 30 | $29.7M | +22.9% | — | −$52.4M | −$61.9M | — | -1.20 | −$56M | $491K | −$56.5M | Nov 6 |
| Q2 2025 · Jun 30 | $21.4M | −4.2% | — | −$63.3M | −$70.9M | — | -1.38 | −$49.3M | $391K | −$49.7M | Aug 6 |
| Q1 2025 · Mar 31 | $89M | +469.8% | — | $12.1M | $6.1M | — | 0.12 | $33.6M | $1M | $32.6M | May 14 |
| Q4 2024 · Dec 31derived | $21.2M | −4.5% | 70.2% | −$51.4M | −$51.2M | — | -1.00 | −$31.6M | $1.1M | −$32.7M | Mar 5 |
| Q3 2024 · Sep 30 | $24.2M | −16.3% | 48.8% | −$62.1M | −$59.6M | — | -1.17 | −$40.5M | $326K | −$40.9M | Nov 6 |
| Q2 2024 · Jun 30 | $22.3M | — | 52.5% | −$56M | −$53M | — | -1.05 | −$45.5M | $474K | −$46M | Aug 7 |
| Q1 2024 · Mar 31 | $15.6M | — | 72.6% | −$63.9M | −$63.3M | — | -1.38 | −$55.5M | $557K | −$56M | May 12 |
| Q4 2023 · Dec 31derived | $22.2M | — | 49.4% | −$63.9M | −$62.9M | — | -1.42 | −$40.8M | $1.1M | −$41.9M | Mar 13 |
| Q3 2023 · Sep 30 | $28.9M | — | 57.2% | −$65M | −$61.9M | — | -1.41 | −$49.4M | $1.4M | −$50.8M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $170.4M | — | −$161.2M | −$193.9M | -113.8% | -3.76 | −$124M | $2.4M | −$126.4M | — | — |
| FY2024 · to Dec 31 | $83.3M | 59.7% | −$233.3M | −$227.1M | -272.5% | -4.59 | −$173.1M | $2.4M | −$175.6M | — | — |
| FY2023 · to Dec 31 | $90.2M | 58.8% | −$268.1M | −$263.5M | -292.0% | -6.02 | −$218.4M | $10M | −$228.4M | — | — |
| FY2022 · to Dec 31 | $112.7M | 51.6% | −$262.9M | −$280.3M | -248.7% | -6.50 | −$207.5M | $30.7M | −$238.2M | — | — |
| FY2021 · to Dec 31 | $470.3M | 89.0% | $160M | $127.8M | 27.2% | 2.91 | $218.9M | $84.2M | $134.7M | — | — |
| FY2020 · to Dec 31 | $154.6M | 76.9% | −$119.2M | −$111.3M | -72.0% | -2.98 | −$54.1M | $26.9M | −$80.9M | — | — |
Every number comes from REGENXBIO Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.